benzoyl chloride pyridine | 7379-54-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzoyl chloride pyridine
• 英文别名: pyridine benzoyl chloride；Benzoyl chloride--pyridine (1/1)；benzoyl chloride;pyridine
• CAS: 7379-54-6
• 化学式: C₅H₅N*C₇H₅ClO
• 分子量: 219.671
• InChiKey: NQOIPEBCWBNSJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.15
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzoyl chloride pyridine 、 硫化氢 以 petroleum ether 为溶剂， 生成 硫化苯甲酰
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: S: SVol.4a/b, 1.3.11.5, page 300 - 301

  摘要：

  DOI：

文献信息

• [EN] NANOPARTICLE FORMULATIONS AND USES THEROF<br/>[FR] FORMULATIONS DE NANOPARTICULES ET LEURS UTILISATIONS
  申请人：ABRAXIS BIOSCIENCE LLC

  公开号：WO2010118365A1

  公开（公告）日：2010-10-14

  The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.

  本发明提供了包含纳米粒子的组合物，其中包括：1）药物，如疏水性药物衍生物；和2）载体蛋白。还提供了使用这些组合物治疗疾病（如癌症）的方法，以及套件和单元剂量。
• Apoptotic compounds
  申请人：Board of Regents, The university of Texas System

  公开号：US20040077542A1

  公开（公告）日：2004-04-22

  The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX 1 , wherein X 1 is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX 1 , wherein X 1 is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis. The invention also provides assays for identifying agents which modulates the interaction of an AV peptoid with an IAP, active compounds identified in such screens and their use in the foregoing compositions and therapeutic methods.

  本发明提供了增强致病细胞凋亡的方法和组合物。一般方法包括将细胞与有效量的AV肽类接触，其中AV肽类是包含AX1的肽类，其中X1为V、I或L，或其肽类类似物，通过IAP结合、procaspase-3激活或促进凋亡等测量方式与凋亡抑制蛋白（IAP）相互作用，从而增强致病细胞的凋亡。所述组合物包括在制剂中含有治疗有效量的AV肽类和药学可接受的载体的制药组合物，其中AV肽类是包含AX1的肽类，其中X1为V、I或L，或其肽类类似物，通过IAP结合、procaspase-3激活或促进凋亡等测量方式抑制凋亡抑制蛋白（IAP）的活性。本发明还提供了用于识别调节AV肽类与IAP相互作用的试剂的测定方法，以及在此类筛选中鉴定出的活性化合物及其在上述组合物和治疗方法中的应用。
• Guanidinium functionalized oligomers and methods
  申请人：——

  公开号：US20030092046A1

  公开（公告）日：2003-05-15

  The present invention provides oligomers which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligomer is modified to include a guanidinium group. These oligomers are useful for diagnostic, therapeutic and investigative purposes.

  本发明提供了寡核苷酸，它们与RNA或DNA的选定序列具有特异性杂交性，其中至少一个核苷酸基团被修饰以包括一种鸟氨酸基团。这些寡核苷酸对于诊断、治疗和调查目的非常有用。
• Processes for the production of polycyclic fused ring compounds
  申请人：Vu Phong

  公开号：US20060281934A1

  公开（公告）日：2006-12-14

  The present invention provides processes for the production of polycyclic fused ring compounds. The polycyclic fused ring compounds are produced by protecting a polycyclic fused ring polyol with a bridging silicon-based protecting group and attaching a suitable side chain. Novel polycyclic fused ring compounds and intermediate compounds are also described.

  本发明提供了生产多环融合环化合物的方法。这些多环融合环化合物是通过用桥接硅基保护基保护多环融合环多醇并连接适当的侧链来生产的。还描述了新型多环融合环化合物和中间化合物。
• Processes for the preparation of paclitaxel
  申请人：Vu Phong

  公开号：US20060281933A1

  公开（公告）日：2006-12-14

  The present invention provides processes for the production of paclitaxel. Paclitaxel is produced by protecting the C(7) and the C(10) hydroxy groups of 10-DAB with a bridging silicon-based protecting group. The resulting 7,10-protected 10-DAB derivative is then derivatized and deprotected to form paclitaxel.

  本发明提供了生产紫杉醇的工艺。通过使用基于硅的桥接保护基保护10-DAB的C（7）和C（10）羟基，生产紫杉醇。然后将得到的7,10-保护的10-DAB衍生物进行衍生化和去保护，形成紫杉醇。